Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pregnancy does not increase melanoma recurrence risk

DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.

Key clinical point: Pregnancy after melanoma does not appear to increase risk for melanoma recurrence.

Major finding: The rate of pregnancy for women with melanoma was 15.8%, compared with 13.6% for controls (P less than .001).

Study details: A retrospective study of claims database records on 11,801 women with melanoma and an equal number of matched controls.

Disclosures: The study was supported by a Barsumian Trust grant; the authors reported having no conflicts of interest.

Read the article.

Citation:

DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.

This Week's Must Reads

President Trump requests $500 million for pediatric cancer, Trump D. State of the Union Address, Feb. 5, 2019.

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.

A shift in Medicare drug coverage may boost costs for patients, Hwang TJ et al. JAMA Int Med. 2019. doi: 10.1001/jamainternmed.2018.6417.

Must Reads in Melanoma

Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514

Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9

Nivolumab safe and effective for cancer patients with HIV, Gobert et al. ESMO 2018, Abstract 1213P_PR.

Nivolumab plus ipilimumab ups survival in melanoma patients with brain mets, Tawbi HA et al. N Engl J Med. 2018 Aug 23. doi: 10.1056/NEJMoa1805453

Pregnancy does not increase melanoma recurrence risk, DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.